NCT02392364已完成4 期
Treat and Extend Versus Dosing Every Eight Weeks With Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema (EVADE Study)
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 2
- 主要终点
- BCVA Change
研究概览
简要总结
The purpose of this study is to compare the safety and efficacy of intravitreal Eylea injections at a set interval, versus a variable dosing schedule (likely longer than one month), based on a specific individual's disease progression. There will be approximately 50 men and women at least 18 years of age, diagnosed with type 1 or type 2 diabetes, taking part in this study at 5 locations in the United States.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults 18 years and older with Type 1 or Type 2 diabetes mellitus
- •Patients with diabetic macular edema involving the center of the macular in the study eye (CST must measure at least 350µm on Heidelberg SDOCT, or 333µm on Cirrus SDOCT)
- •Decrease in vision determined to be primarily due to DME in the study eye
- •BCVA ETDRS letter score 78 to 24 (20/32 to 20/320) in the study eye
- •Willing and able to comply with clinical visits and study related procedures
- •Willing and able to provide signed informed consent
排除标准
- •History of vitreoretinal surgery in the study eye
- •Laser photocoagulation (panretinal or macular) in the study eye within 90 days of baseline
- •Previous use of intraocular or periocular corticosteroids in the study eye within 90 days of baseline
- •History of intravitreal anti-VEGF treatments in the study within 90days prior to baseline (not including prior intravitreal aflibercept injection [see exclusion criteria #5])
- •Any history of intravitreal aflibercept
- •Active proliferative diabetic retinopathy (PDR) in the study eye
- •History of idiopathic or autoimmune uveitis in the study eye
- •Cataract surgery in the study eye within 90 days of baseline
- •Aphakia in the study eye
- •Yttrium aluminum garnet (YAG) capsulotomy in the study eye within 30 days of baseline
- •Any intraocular surgery in the study eye within 90 days of day 1
- •Vitreomacular traction or epiretinal membrane in the study eye that is thought to affect central vision
- •Current iris neovascularization, vitreous hemorrhage, or traction retinal detachment in the study eye
- •Pre-retinal fibrosis involving the macula in the study eye
- •Uncontrolled glaucoma (defined as any patient who has had filtration surgery in the past, or likely to need filtration surgery in the future, or has IOP ≥30mmHg)
- •Myopia of a spherical equivalent prior to any possible refractive or cataract surgery of ≥-8 diopters
- •Concurrent disease in the study eye, other than DME, that could compromise BCVA, require medical or surgical intervention during the study period, or could confound interpretation of the results (including retinal vascular occlusion, retinal detachment, macular hole, or choroidal neovascularization of any cause)
- •Ocular media of insufficient quality to obtain fundus and SDOCT images
- •Current treatment for a systemic infection
- •Administration of systemic anti-angiogenic agents within 180 days of baseline
- •Uncontrolled diabetes mellitus, in the opinion of the investigator
- •Uncontrolled blood pressure (define as systolic >180mmHg, or diastolic >110mmHg while patient is sitting)
- •History of CVA or MI within 180 days of baseline
- •Renal failure requiring dialysis or renal transplant
- •Known serious allergy to fluorescein
- •Participation in an investigational study within 30 days prior to baseline that involved treatment with any drug (excluding vitamins and minerals) or device
- •Any women who are pregnant, breast-feeding, or attempting to become pregnant
- •Sexually active men* or women of childbearing potential** who are unwilling to practice adequate contraception during the study (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device [IUD]; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly) *Contraception is not required for men with documented vasectomy. **Postmenopausal women must be amenorrheic for at least 12 months in order not to be considered of child bearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.
研究组 & 干预措施
Variable Treatment Dosing Arm
Active Comparator
Group 1 will receive injections every 4 weeks until diabetic macular edema on the OCT is decreased and stable. At that point, the length of time between injections may increase, depending on how the study eye is doing. The interval between study eye treatments may maintain, increase, or decrease once the variable treatment dosing has begun. This will be determined by an algorithm designed into a computer program
干预措施: Intravitreal Aflibercept Injection (Drug)
Monthly Treatment Arm
Active Comparator
Group 2 will receive 5 intravitreal injections, monthly, for the first 5 months of the study. After those initial injections, visits/treatment will be every 8 weeks.
干预措施: Intravitreal Aflibercept Injection (Drug)
结局指标
主要结局
BCVA Change
时间窗: Week 0 to Week 52
Change in mean BCVA from baseline to week 52
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
4 期
Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD)Retinal Pigment Epithelial Detachment Secondary to Age-related Macular DegenerationNCT02142296Lawson Health Research Institute37
终止
2 期
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)Wet Macular DegenerationChoroidal NeovascularizationNCT03452527Iconic Therapeutics, Inc.15
Unknown
4 期
Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910Exudative Age-related Macular DegenerationNCT01961414Palmetto Retina Center, LLC45
已完成
不适用
Intravitreal Triamcinolone and Moxifloxacin Injection After Cataract SurgeryPharmacological ActionNCT05428683Emad Abdel Aal Saliem84
终止
2 期
A Multicenter, Proof-Of-Concept Study Of Intravitreal AL-78898A In Patients With Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD)Geographic AtrophyNCT01603043Alcon Research10